Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065312 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00065312: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00065312 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00065312, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
Interventions
- DRUG naveglitazar
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00065312 record still lists
NCT00065312 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which naveglitazar is the first listed.
NCT00065312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00065312 about?
NCT00065312 is a clinical study titled "An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes". The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
What is the current status of trial NCT00065312?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00065312?
The interventions under investigation include: naveglitazar (DRUG).
Who is sponsoring clinical trial NCT00065312?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.